Paradigm Biopharma reaches clinical milestone in osteoarthritis trial. The biotech company has enrolled fifty percent of patients needed for its Phase III study investigating injectable drug iPPS, unlocking access to interim results by Q3 2026 instead of waiting for full trial completion. This accelerated timeline provides investors with early efficacy data and allows time to refine the study based on findings. The PARA_OA_012 trial will enroll 466 participants globally, measuring pain reduction and physical function improvements as primary endpoints. Chief Paul Rennie emphasized the refined trial design incorporates regulatory feedback and scientific expertise to strengthen detection of treatment effects while addressing placebo response challenges common in osteoarthritis studies. The stock last traded at 26.5 cents.
Post from MarketNews_en
Log in to interact with content.